ホーム>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>GW4064

GW4064

カタログ番号GC10975

GW4064は、合成FXRアゴニストとして、胆汁うっ滞性肝疾患、メタボリックシンドローム、およびアルコール性肝疾患の治療に使用された。

Products are for research use only. Not for human use. We do not sell to patients.

GW4064 化学構造

Cas No.: 278779-30-9

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$47.00
在庫あり
5mg
$36.00
在庫あり
10mg
$62.00
在庫あり
50mg
$177.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

GW4064, as a synthetic FXR agonist, was used for treatment of cholestatic liver diseases, metabolic syndrome and alcoholic liver disease.[1]

In vitro experiment it shown that the IC50 values of GW4064 in SW620 and HT-29 cells were 7.6 μM and 13.8 μM, respectively.[2] In vitro efficacy test it indicated that the GW4064 response was concentration dependent (EC50 values after 24 hours of treatment were 0.012 μM and 0.015 μM, respectively) on CRE and NFAT-RE luciferases.[3] GW4064 dose dependently enhanced the basal cAMP level with EC50 of 0.241 μM, and suppressed forskolin-induced cAMP accumulation with IC50 of 0.07 μM.[3]

In vivo study it demonstrated that Rats in the treatment group received an interperitoneal GW4064 injection of 30 mg/kg every other day for 2 wk, GW4064 could correct BA dysmetabolism to alleviate hepatotoxicity in SBR animals. In the meanwhile, GW4064 intervention decreased the fecal bile excretion and elevated plasma/hepatic conjugated BA levels. It also increased the reabsorption of conjugated BAs by inducing apical sodium-dependent bile salt transporter expression in the ileum.[4] In vivo, treatment with 30 mg/kg for 7 consecutive days intraperitoneally, GW4064 alleviated social deficits in BTBR mice and modulated selective aspects of the composition of the gut microbiota.[5] Mice were injected 20 mg/kg GW4064 intraperitoneally result in that decreased hepatic inflammation in the LPS-induced murine liver injury model.[6].

References:
[1]. A.S. Alawad, C. Levy. FXR agonists: from bench to bedside, a guide for clinicians Dig. Dis. Sci., 61 (12) (2016), pp. 3395-3404.
[2]. Guo J, et al. GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis. Biochem Biophys Res Commun. 2021 Apr 9;548:60-66.
[3]. Singh N, et al. Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors. Mol Endocrinol. 2014 May;28(5):659-73.
[4]. Cao Y, et al. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection. Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G108-G115.
[5]. Liu J, et al. GW4064 Alters Gut Microbiota Composition and Counteracts Autism-Associated Behaviors in BTBR T+tf/J Mice. Front Cell Infect Microbiol. 2022 Jun 22;12:911259.
[6]. Liu HM, et al. GW4064 attenuates lipopolysaccharide induced hepatic inflammation and apoptosis through inhibition of the Toll like receptor 4 mediated p38 mitogen activated protein kinase signaling pathway in mice. Int J Mol Med. 2018 Mar;41(3):1455-1462.

レビュー

Review for GW4064

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GW4064

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.